Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 2Interventional 1

Sponsor

Cancer Type

Gastrointestinal 314Thoracic 233Breast 111Gynecologic 80Head & Neck 77Lymphoid 66Other hematologic neoplasm 55CNS 44Genitourinary 36Sarcoma 32Other solid neoplasm 30Tumor-Agnostic 23Dermatologic 17Plasma cell 10Myeloid 7Classical hematology 6Other 3Endocrine 2Other neoplasm 1NET 1

Conditions

Advanced Pancreatic Neuroendocrine Tumor 1

Interventions

lutetium Lu 177 dotatate 41Everolimus 38Magnetic Resonance Spectroscopy 18Temozolomide 17lanreotide 16gallium Ga 68 dotatate 15Octreotide 14pembrolizumab 13Nivolumab 13Capecitabine 12cabozantinib 11177Lu-octreotide, DOTA(0)-Tyr(3)- 11surufatinib 9pasireotide 9Sunitinib 9Specimen Handling 9Positron Emission Tomography Computed Tomography 93-Iodobenzylguanidine 9Lutetium-177 8Carboplatin 8amino-acid, glucose, and electrolyte solution 6Ipilimumab 6Ga(III)-DOTATOC 6Fluorodeoxyglucose F18 6Etoposide 6Cisplatin 690Y-octreotide, DOTA-Tyr(3)- 6lenvatinib 5copper dotatate CU-64 5Injections 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Drug Therapy × NET × Clear all
NCT06246630 2024-05-16

In Vitro Organoid Drug Sensitivity-Guided Treatment for Advanced Pancreatic Neuroendocrine Tumor

Ruijin Hospital

Phase NA Recruiting
20 enrolled
EndocrineGastrointestinalNET

Advanced Pancreatic Neuroendocrine Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡